Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection

NCT02038881 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT02038881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02038881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection
Lead sponsor
Bavarian Nordic
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2014
Completion date
May 10, 2017
Enrollment
87 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

smallpox